When competitive intelligence is predictive rather than reactive, biopharma companies can grab the edge

In the dynamic global biopharma landscape, competitive intelligence (CI) is as indispensable as ever.

Read more >

NGS, maybe, sort of, sometimes clinic ready

Detailed genomic profiling is a sine qua non of precision medicine, and at tertiary cancer centers, the comprehensive profiling of tumors and matched germline DNA is becoming ever more routine.

Read more >

Victories in Huntington’s disease few and far between, but resolve remains undimmed

The HD community has tempered its expectations but not its optimism.

Read more >

Innovation comes with hefty price tag as biopharma R&D spend climbs

To keep biopharmaceutical innovation churning requires mountains of cash. Companies will need to invest as much as $2.5 billion over a 10- to 15-year period in order to bring a new therapy to the marketplace, according to a 2014 study conducted by the Tufts Center for the Study of Drug Development.

Read more >

The 3 Rs of cancer research: rigor, reproducibility and robustness

As scientists gathered at the 2017 meeting of the American Association for Cancer Research (AACR) in Washington in early April to learn about the latest advances in cancer research, one of the questions was how much of that research would hold up to attempts to reproduce it.

Read more >